NeoStem Announces Participation in Multiple January Conferences

NEW YORK, Jan. 4, 2012 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that the Company and Progenitor Cell Therapy ("PCT"), will be presenting at four upcoming January conferences: Biotech Showcase 2012, BOCEMb 2012 - Noble Financial Capital Markets Equity Conference, ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies, and Phacilitate's Cell & Gene Therapy Forum 2012.

Dr. Robin L. Smith commented, "This list of January events demonstrates our widespread involvement in various industry forums and investor conferences that give us the opportunity to highlight our cell therapy industry expertise designed to put us at the forefront in transforming chronic disease through the application of cell based medicine while strategically providing revenues from our contract cGMP manufacturing of a variety of product candidates under development."

Biotech Showcase 2012 – January 10, 2012, San Francisco, California – Park 55 Wyndham

8:00 – 9:30 AM – Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present as part of a panel discussion entitled "Regenerative Medicine State of the Industry Briefing."

10:30 AM – Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present on NeoStem in Track C.

9:30 – 11:00 AM – Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem, will present on Amorcyte, a NeoStem company developing novel treatments for cardiovascular disease, as part of a panel discussion entitled "Cardiovascular, AMI and PAD—Part 1".

ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies – January 11-13, 2012, San Diego, California – Catamaran Resort Hotel

10:40 AM on Thursday, January 12 – Dr. Robert A. Preti, President of PCT, will chair a session titled "Process Development Challenges for Autologous Cell Therapies".

11:55 AM on Friday, January 13 – Dr. Robert A. Preti, President of PCT, will speak in Session 6, "Business Models", about "Considerations in scale up of autologous and allogeneic cell therapies: implications to cost of goods".

BOCEMb 2012 - Noble Financial Capital Markets Equity Conference – January 17-18, 2012, Hollywood, Florida – Hard Rock Hotel

12:00 PM on Wednesday, January 18 – Jason Kolbert, NeoStem's Vice President of Strategic Business Development, will present on NeoStem.

Phacilitate Cell & Gene Therapy Forum 2012 – January 30 - February 1, 2012, Washington DC – The Grand Hyatt

2:10 PM on Monday, January 30 – Dr. Sanjin Zvonic, Director, Technology & Business Development, PCT, will present during a session titled "Beyond scale-up: Managing the delivery and bedside integrity of cryopreserved cell therapy products".

3:25 PM on Tuesday, January 31 – Dr. Robert A. Preti, President of PCT, will present during a session titled "Cell therapy and tissue engineered product translational R&D strategy: What advice can companies that have successfully advanced into clinical trials impart?"

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, Inc., also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and  has commenced enrollment in a Phase 2 trial for the preservation of heart function after a heart attack.  Amorcyte expects to begin a Phase 1 clinical trial in 2012 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson.  NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's prospectus supplement filed with the Securities and Exchange Commission on September 30, 2011. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

SOURCE NeoStem, Inc.